Associazione Nazionale Medici Cardiologi Ospedalieri

CONGRESS ABSTRACT

CONGRESS ABSTRACT

Categorie
SHORT-TERM VARIABILITY OF THE MECKI SCORE IN PATIENTS WITH HEART FAILURE
Anno:
2026
Background. Cardiopulmonary exercise testing (CPET) provides several prognostic parameters in patients with heart failure (HF), including peak VO₂, VE/VCO₂ slope, and anaerobic threshold (AT). However, the reproducibility of these variables may be affected by effort-dependence, operator variability, and methodological issues. Since the MECKI score integrates CPET with laboratory and…
STRUCTURAL REVERSE REMODELING WITH VERICIGUAT IN HFREF: IS THE BENEFIT DEPENDENT ON THE DEGREE OF BASELINE GUIDELINE-DIRECTED MEDICAL THERAPY OPTIMIZATION?
Anno:
2026
Background: Vericiguat, a soluble guanylate cyclase (sGC) stimulator, has demonstrated a significant reduction in cardiovascular events in heart failure with reduced ejection fraction (HFrEF). While recent real-world evidence suggests its potential to promote structural reverse remodeling, it remains debated whether its impact on structural remodeling is a synergistic effect…
TRENDS IN MEDICAL THERAPY OPTIMIZATION IN HFREF: DATA FROM THE PONTE SC-SCA REGISTRY
Anno:
2026
Background & Study Aim. In recent years, substantial progress has been achieved in the treatment of heart failure (HF), particularly in patients with reduced ejection fraction (HFrEF). Among the objectives of the PONTE SC/SCA registry is the evaluation of adherence to guideline-recommended therapies through both prospective and retrospective analyses….
NT-PROBNP AS A MIRROR OF HEMODYNAMIC RESERVE: INSIGHTS FROM CPET WITH NON-INVASIVE CARDIAC OUTPUT MONITORING IN PATIENTS WITH HF AND REDUCED LVEF
Anno:
2026
BACKGROUND: N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a well-established biomarker in heart failure (HF), reflecting ventricular filling pressures and neurohormonal activation. Although it is widely used for risk stratification, its relationship with dynamic parameters derived from cardiopulmonary exercise testing (CPET) and with contractile reserve has not been fully clarified….
IMPACT OF SGLT2 INHIBITORS ON LEFT VENTRICULAR FILLING PRESSURES ASSESSED BY THE COMBINATION OF LEFT ATRIAL STRAIN AND DOPPLER MEASURES IN PATIENTS WITH HEART FAILURE REDUCED EJECTION FRACTION
Anno:
2026
Background. The type 2 sodium-glucose cotransporter inhibitors (SGLT2i) are milestone drugs in the treatment of heart failure with reduced ejection fraction (HFrEF). However, the mechanisms responsible for their beneficial effects are still to be clarified. Aim of the study. To evaluate the effect of SGLT2i therapy on left ventricular…
OPTIMIZATION OF MEDICAL THERAPY IN PATIENTS WITH HFREF: DATA FROM THE PONTE SC-SCA REGISTRY
Anno:
2026
Background & Study Aim: The PONTE SC/SCA registry was designed to evaluate the outcomes of a structured outpatient follow-up program integrating hospital and community care for patients with heart failure (HF) or those recently hospitalized for acute coronary syndrome (ACS). The aim of the present study was to analyze…